Clinical trials
Phase 3 Precancerous Conditions trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2023 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 2 |
| Terminated | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 4 |
| Almirall, S.A. | 3 |
| Jonsson Comprehensive Cancer Center | 2 |
| NCIC Clinical Trials Group | 2 |
| SWOG Cancer Research Network | 2 |
| Sun Pharmaceutical Industries, Inc. | 2 |
| AIDS Malignancy Consortium | 1 |
| Applied Genetics | 1 |
| Atossa Therapeutics, Inc. | 1 |
| Barts and the London School of Medicine and Dentistry | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precancerous Conditions | 32 |
| Leukemia | 10 |
| Lymphoma | 10 |
| Multiple Myeloma | 10 |
| Neoplasms, Plasma Cell | 10 |
| Hodgkin Disease | 8 |
| Immunoblastic Lymphadenopathy | 8 |
| Immunoglobulin Light-chain Amyloidosis | 8 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Lymphoma, Follicular | 8 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.